Drugs / GFH925
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05756153 | Apr 2023 → Apr 2025 | non-small cell lung carcinoma | Genfleet Therapeutics (Shanghai) Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT05005234 | Sep 2021 → Feb 2023 | — | Innovent Biologics (Suzhou) Co. Ltd. | Completed | Met primary |
Press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-11-24 | Genfleet Therapeutics (Shanghai) Inc. | 国内首个KRAS G12C抑制剂（GFH925）新药上市申请获正式受理并纳入优先审评 genfleet.com ↗ |
| 2023-01-05 | Genfleet Therapeutics (Shanghai) Inc. | GFH925（KRAS G12C抑制剂）获CDE突破性疗法认定，治疗晚期非小细胞肺癌患者 genfleet.com ↗ |
| 2022-11-12 | Genfleet Therapeutics (Shanghai) Inc. | 2022 CSCO | GFH925（KRAS G12C抑制剂）单药I期试验最新结果公布 genfleet.com ↗ |
| 2021-09-02 | Innovent Biologics (Suzhou) Co. Ltd. | Innovent and GenFleet Announce Exclusive Global License Agreement for GFH925 (KRAS G12C Inhibitor) innoventbio.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GFH925 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05756153 ↗ |